Prolyl Endopeptidase: Difference between revisions
| Line 35: | Line 35: | ||
Prolyl endopeptidases are a promising therapeutic agent due to their ability to degrade the protein rich [http://en.wikipedia.org/wiki/Prolamin prolamins] and inhibit the inflammatory reaction. An early idea for treatment is to orally administer certain microbial PEPs which could directly degrade [http://en.wikipedia.org/wiki/Prolamin prolamins] in the intestine and reduce the auto-immune response. The key for this possibility is to be able to protect the PEPs from being degraded by gastric acids while allowing them to be able to be functional in the small intestine once the acidity is decreased. | Prolyl endopeptidases are a promising therapeutic agent due to their ability to degrade the protein rich [http://en.wikipedia.org/wiki/Prolamin prolamins] and inhibit the inflammatory reaction. An early idea for treatment is to orally administer certain microbial PEPs which could directly degrade [http://en.wikipedia.org/wiki/Prolamin prolamins] in the intestine and reduce the auto-immune response. The key for this possibility is to be able to protect the PEPs from being degraded by gastric acids while allowing them to be able to be functional in the small intestine once the acidity is decreased. | ||
Research by Ehren, Govindarajan, Morón, Minshull, and Khosla CITE has shown the ability to engineer the prolyl endopeptidase of ''Sphingomonas capsulata'' to increase the activity of this PEP under simulated gastric conditions showing the relevance of PEPs as a potential therapeutic agent for [http://en.wikipedia.org/wiki/Coeliac_disease Celiac Disease]. | |||
=== Neurological Disorders === | === Neurological Disorders === | ||